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creativecommons.org/reduced or reversed in very old age. The Protected Survivor Model predicts this interaction due to
enhanced survival of those with extended risk factor duration. In a younger sample, this study examines
the association of cognition with the mean hemoglobin A1c risk factor over the time at risk, according to
its duration.
Methods: The interaction of mean hemoglobin A1c (average 5 9.8%), evaluated over duration
(average5 116.8 months), was examined for overall cognition and three cognitive domains in a sam-
ple of 150 “young-old” veterans (mean age 5 70) with type 2 diabetes.
Results: The predicted interactions were significant for overall cognition and attention, but not
executive functions/language and memory.
Discussion: Findings extend the Protected Survivor Model to a “young-old” sample, from the very
old. This model suggests focusing on individuals with good cognition despite prolonged high risk
when seeking protective factors.
Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article
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Type 2 diabetes (T2D) affects more than 25% of the adults
aged 65 years or older [1], associated with nearly twice the risk
of developing cognitive impairment, dementia, and Alzheim-
er’s dementia. Previous studies have found that while aging is
one of the major risk factors for dementia, among patients
with T2D, hyperglycemia, and hypoglycemia, and durationuthor. Tel.: (718) 584-9000 x 1700; Fax: (718) 562-
remy.silverman@mssm.edu
/j.trci.2019.11.009
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licenses/by-nc-nd/4.0/).of the diabetes is an additional risk factor for cognitive impair-
ment [2–5]. In a few studies of very old age (.75 years)
patients with T2D, the risk of a bad cognitive outcome was
diminished [6] or even reversed [7–10], in contrast to
“young-old” (average age ,75) samples [11].
The Protected Survivor Model [12] was developed to
explain these changes in outcomes measured at different
points in late life [10,13–15]. This model assumes that a
large majority of a birth cohort are vulnerable to the
presence of a risk factor, but a minority have protection
against the bad outcome despite the presence of the risk
factor. With increasing age, “survivors” are those cohort. This is an open access article under the CC BY-NC-ND license (http://
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bad outcome. Unprotected individuals with high levels of risk
factor are less likely to survive. Over time, an increasing
proportion of survivors are either protected individuals—
regardless of the risk factor level—or unprotected individuals
with low risk factor levels. Moreover, those with high risk
factor levels are increasingly likely to be protected, so that
the observed association of high risk with bad outcome is
diminished or even reversed with increasing age. In addition,
if the risk factor is associated with higher mortality, this
increasing proportion of protection is further accelerated.
According to the Protected Survivor Model, diminished
or even reversed risk association is clearest in “oldest-old”
(at least age 85) survivors. In addition to late old age as a
measure of extended survival, the model can also be applied
to duration of risk regardless of age. This extension of the
model—from age to duration of high risk as a measure of
survival—is the focus of the present study of a relatively
young sample. It examines how the association of cognitive
performance with hemoglobin A1c (HbA1c; a measure of
average blood glucose over 3 months) changes according
to duration of diabetes. In individuals with T2D, medication
and/or lifestyle may reduce HbA1c down to nondiabetic
levels (,6.5%). Many studies of individuals without
[16,17] as well as those with T2D [18] have implicated rela-
tively high levels of HbA1c as a risk factor for dementia,
including Alzheimer’s disease, or cognitive impairment
and decline.
The present study of a young-old samplewith diabetes in-
vestigates how the association of cognitive performance
with mean HbA1c over time differs according to survivor-
ship indexed by T2D duration. Its participants (aged
551 years) were enrolled in a clinical trial, “Computerized
Cognitive Training to Improve Cognition in Diabetic Elderly
Veterans” [19] and assessed at baseline. Based on the Pro-
tected Survivor Model, we hypothesized an interaction of
T2D duration and HbA1c for cognitive performance: rela-
tively good cognition among those with high levels of both
risk factors, after taking account of the separate effects of
T2D duration and HbA1c.2. Methods
2.1. Participants in the clinical trial
The clinical trial—conducted at Bronx, NY and Ann
Arbor, MI Veterans Affairs Medical Centers (VAMC)—
enrolled US military veterans aged at least 55 years with a
diagnosis of T2D identified in their VA medical records
[19]. Participants were required to be free of dementia;
any major medical, psychiatric, or neurological conditions
that affect cognitive performance; and severe impairment
in vision or hearing. The clinical trial focuses on efficacy
for better T2D self-care, so the Diabetes Self-Management
Questionnaire [20] screened for self-reported deficits in
self-care; a score of 18, reflecting deficits below themaximum of 20, was required. Women were not excluded
but were rare (3%). The VA’s Central Institutional Review
Board approved the study as did the Research and Develop-
ment committees of both VAMCs, and all participants pro-
vided signed informed consent.
2.2. Cognitive and neuropsychological measurements
Before randomization in the clinical trial, participants
were screened for dementia and overall cognitive func-
tioning; a battery of neuropsychological tests assessed over-
all cognitive function as well as specific cognitive domains.
2.2.1. Clinical dementia rating scale
Severity of cognitive-related functional impairment is
assessed from the participant and an informant. “No de-
mentia” (0) or “questionable dementia” (0.5) is required
for inclusion—higher scores (1 to 3) indicate severity of
a definite dementia [21].
2.2.2. Mini–Mental State Examination
This 30-point screening questionnaire assesses global
cognition. A score 25 or above was required [22].
2.2.3. Neuropsychological battery
Nine tests (Word List Memory, Logical Memory (story
A), Target Cancellation Tests, Trail Making Test, Digit Sym-
bol Substitution Test, Digit Span, Boston Naming Test, Ver-
bal Fluency Test, Similarities) yielded 16 scores associated
with the cognitive domains of executive functions, language,
memory, and attention [23].
2.3. Diabetes diagnosis and HbA1c measurements
In 1999, the VA fully implemented its electronic medi-
cal record database, the Centralized Patient Record System
(CPRS) [24]. Among many other features, for every VA pa-
tient, theCPRS includes diagnoses documented by physicians,
laboratory values with associated dates, and demographic in-
formation. For all participants in the clinical trial, we obtained
all HbA1c measurements as performed by the VA clinical lab-
oratory, and diagnoses of medical conditions, including T2D,
from the CPRS.
2.4. Required data for the present study
Clinical trial participants were required to have complete
baseline data on demographics (self-reported age, sex, years
of education), clinical dementia rating (CDR) and Mini–
Mental State Examination scores, and all 16 neuropsycho-
logical test scores. Duration of T2D was estimated as the
number of days from the date of the first recorded CPRS
measurement of HbA1c to the date of the last HbA1c mea-
sure at or before the cognitive assessment. A minimum of
three HbA1c measures were required. At least one HbA1c
measurement had to be at least 91 days and one-sixth of
the T2D duration from both the first and the last
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intermediate measurements were very near the first or last
measurement, almost as if only two times were assessed.
The primary analyses used the mean HbA1c, called here
simply HbA1c, as the summary for each participant.2.5. Statistical methods
The first principal component of a factor analysis of the
neuropsychological tests was used as the estimate of overall
cognition, the primary cognitive outcome. Scree plot com-
parison of the eigenvalues and interpretation of orthogonal
Varimax factors were used to define two to four uncorrelated
secondary cognitive outcomes—cognitive domain scores
possibly combining memory, executive functions, language,
and attention. For each of the cognitive scores, hierarchical
regression analysis entered six predictors: CDR status
(step 1), age (step 2), years of education (step 3), T2D dura-
tion (in months) (step 4), HbA1c (step 5), and the product of
T2D duration and HbA1c (step 6)—which represented their
interaction, after controlling for both variables. Step 6 is the
test of the hypothesis of this study—an interaction of T2D
duration and HbA1c, with relatively good cognition among
thosewith high levels of both risk factors, indicated by a pos-
itive partial correlation.
Other risk factors for cardiovascular disease, many substan-
tially intercorrelated with HbA1c, were not included as cova-
riates. Our interest was to investigate cognition of participants
with both high HbA1c with long T2D duration. Relatively
good cognition would nominate this combination as a possible
“marker” for a cognitive protective factor according to the Pro-
tected SurvivorModel. Thus, we did not seek to limit the effect
of the combination of high HbA1c and long T2D duration to
its unique contribution to cognition, beyond the effect of other
cardiovascular risk factors. The number of women was so
small that inclusion of sex as an additional covariate,
commonly used in studies of cognition, was not appropriate.
To operationalize the hypothesized “high levels of both
risk factors” in an interaction, the entire sample was dichot-
omized twice into majority “lower risk” and minority “high
risk” groups, using the lower limit of the upper third of T2D
duration or HbA1c. These two dichotomies created four sub-
groups: shorter T2D duration/lower HbA1c, shorter T2D
duration/high HbA1c, long T2D duration/lower HbA1c,
and long T2D duration/high HbA1c. Using dichotomized
rather than continuous measures of T2D duration and
HbA1c, a 2! 2 analysis of covariance tested their interac-
tion, controlling for CDR, age, and education.
Statistical significance was defined as P , .05. Although
the hypothesis was directional, a two-sided test was used to
take account of a possible opposite result.3. Results
The initial sample of 182 included 176 participants with
complete demographic and neuropsychological data, ofwhom 150 had the required HbA1c measures before the
baseline cognitive assessment.
Principal components analysis of the 16 test scores asso-
ciated with the 9 neuropsychological tests yielded a large
first principal component (33% of total variance); the first
three principal components accounted for 53%. The three
cognitive domains were labelled executive functions/language
(with highest magnitudes of loadings on Letter Fluency, Digit
Symbol, Trails A, Digit Backwards, Trails B, Digit Forward,
Similarities, Category Fluency), memory (Word List: Imme-
diate Recall, Delayed Recall, Recognition; Logical Memory:
Immediate Recall, Delayed Recall), and attention (Target
Cancellation: TMX, Diamond; Boston Naming).
Table 1 presents the demographic, HbA1c, and cognitive
characteristics of the total sample and compares the shorter
(N 5 100) and long (N 5 50) T2D duration subsamples
dichotomized at 157.72 months (about 13 years). The T2D
duration group difference in HbA1c assesses the association
between dichotomized duration group and the continuous
HbA1c. This difference reflected a significant association
between continuous measures of T2D duration and HbA1c
(r 5 0.329, P , .001). It also reflected a significant associa-
tion between dichotomized measures of T2D duration and
HbA1c (phi coefficient 5 0.28, P , .001). These associa-
tions reflect higher values of HbA1c for longer duration.
For the full sample, Table 2 shows the regression
models for the overall cognition score and each of the three
cognitive domain scores. After controlling, a priori, for
CDR status, age, and education (steps 1, 2, and 3), worse
overall cognition was significantly associated with risk
factors of longer T2D duration (step 4) and higher
HbA1c (step 5). These associations were consistent with
previous studies of HbA1c and T2D duration as distinct
risk factors but were not the primary focus of the present
study. The significant positive interaction of T2D duration
and HbA1c (Step 6; P5 .01) confirms the hypothesis of the
study—high levels of both risk factors were associated
with relatively good overall cognition. Not controlling
for CDR, age, and education, the interaction remained sig-
nificant (P 5 .037).
Of the three cognitive domains, only attention had a signif-
icant interaction of T2D durationwith HbA1c (P5 .03). None
of the three cognitive domains was significantly associated
with both risk factors: worse executive functions/language
was significantly associated only with longer T2D duration;
worse memory and attention were significantly associated
only with higher HbA1c.
To visualize the interaction for overall cognition, Fig. 1
shows separate plots of overall cognition by HbA1c for the
shorter and long T2D duration groups, in simple raw data,
not controlling for CDR, age, and education. Within the entire
shorter T2D duration group (lower panel), overall cognition
decreases as HbA1c increases (solid line: r 5 20.364,
P , .001). By contrast, within the entire long T2D duration
group (upper panel), overall cognition increases as HbA1c in-
creases (solid line: r 5 0.281, P 5 .04).
Table 1
Characteristics of veterans with diabetes sample: Total and dichotomized T2D duration group
Characteristic
T2D duration: Total sample
(7.41–215.15 mo.)
Shorter T2D duration
(7.41–157.70 mo.)
Long T2D duration
(157.74–215.15 mo.) Statistic* P value
N 150 100 50
Age (SD) 69.8 (6.3) 69.4 (5.3) 70.7 (8.0) t 5 21.21 .228
Males (%) 146 (97) 97 (97%) 49 (98%) c2 5 0.13 .72
Education y (SD) 14 (3) 14 (2) 14 (3) t 5 20.59 .56
Mean HbA1c (SD) 9.78 (1.42) 9.39 (1.46) 10.57 (0.94) t 5 25.19 ,.001
High HbA1c group (%) 50 (33%) 24 (24%) 26 (52%) c2 5 11.76 ,.001
T2D duration mo (SD) 116.79 (59.61) 82.96 (41.68) 184.56 (16.98) NA
# HbA1c measures (SD) 40 (41) 23 (18) 72 (53) t 5 28.31 ,.001
CDR 5 0 (%) 125 (83%) 86 (86%) 39 (78%) c2 5 1.54 .22
MMSE (SD) 28 (1) 28 (1) 28 (1) t 5 1.25 .21
Overall cognition 0.00 (1.00) 0.17 (1.03) 20.34 (0.85) t 5 3.03 .003
Executive functions/language 0.00 (1.00) 0.18 (0.99) 20.36 (0.93) t 5 3.23 .002
Memory 0.00 (1.00) 0.05 (0.99) 20.10 (1.02) t 5 0.91 .37
Attention 0.00 (1.00) 0.003 (0.995) 20.007 (1.020) t 5 20.57 .96
Abbreviations: CDR, Clinical dementia rating; HbA1c, hemoglobin A1c;MMSE,Mini–Mental State Examination; T2D, type 2 diabetes; NA, not applicable.
*Degrees of freedom: t, 148; c2, 1.
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vations in the lower and high HbA1c subgroups within
each T2D duration group. Within each of the four sub-
groups, the star and associated vertical bars indicate,
respectively, the means of HbA1c and cognition, and the
standard deviation of cognition. The four subgroups also
have separate dotted regression lines. Within the shorter
T2D duration group, overall cognition decreases as
HbA1c increases within both HbA1c subgroups (lower:
HbA1c, r 5 20.26, P , .02; high: HbA1c, r 5 20.24,
P5 .25). By contrast, within the long T2D duration group,
although overall cognition also decreases within lower
HbA1c (r 5 222, P 5 .31), it increases within high
HbA1c (r 5 0.36, P 5 .07).
Analysis of covariance, controlling for CDR, age, and ed-
ucation, found a strongly significant interaction of dichoto-
mized T2D duration and HbA1c for overall cognition
(F [1, 143] 5 11.55, P , .001), confirming the result for
the continuous measures. Because the shorter T2D duration/
lower HbA1c subgroup was favorable on both risk factors,
it was not surprising that it had the highest estimated overall
cognition score (0.291, N 5 76). The long T2D duration/
high HbA1c subgroup had the next best cognition scoreTable 2
Stepwise multiple regression analyses of overall cognition and cognitive domain
Stepwise entry
Overall cognition
Executive fun
language
Partial r P-value Partial r
1. CDR status 20.37 ,.001 20.23
2. Age 20.09 .27 20.04
3. Education (yr) 0.17 .04 0.20
4. T2D duration (mo) 20.18 .03 20.24
5. Mean HbA1c 20.28 ,.001 20.14
6. HbA1c! T2D duration 0.21 .01 0.13
Abbreviations: CDR, Clinical dementia rating; HbA1c, hemoglobin A1c; T2D,(20.058, N5 26). The other two subgroups had worse cogni-
tion scores: shorter T2D duration/high HbA1c (20.296,
N 5 24) and long T2D duration/lower HbA1c (20.563,
N5 24). Thus, the long T2D duration/high HbA1c subgroup
had better cognition than the subgroups with one favorable
and one unfavorable risk factor, although both risk factors
were unfavorable.
For the attention domain, for which the interaction of
continuous T2D duration and Hb1c was also significant,
analysis of covariance using dichotomized measures of
T2D duration and HbA1c had a nonsignificant interaction
(F [1, 143] 5 2.67, P5 .104). Again, the shorter T2D dura-
tion/lower HbA1c subgroup had the highest estimated over-
all attention score (0.163, N 5 76). The long T2D duration/
high HbA1c subgroup (20.039, N 5 26) did not have the
next best attention score, but it was substantially better
than the combined results for the other two subgroups:
long T2D duration/lower HbA1c (0.052, N5 24) and shorter
T2D duration/high HbA1c (20.527, N 5 24). These
descriptive results suggest that attention for patients with
high levels of both risk factors was—overall—better than
for thosewith only one, so the regression analysis interaction
was in the hypothesized direction.scores
ctions/
Memory Attention
P-value Partial r P-value Partial r P-value
.004 20.35 ,.001 0.02 .82
.60 20.08 .33 20.03 .68
.02 20.02 .82 0.06 .48
.004 0.03 .76 0.003 .98
.09 20.18 .03 210.20 .01
.12 0.08 .33 0.18 .03
type 2 diabetes.
Fig. 1. HbA1c by overall cognition scores divided by duration groups.
Mean HbA1c by overall cognition scores in veterans with T2D dichoto-
mized at the low end of the upper third (157.72 months), creating a long
T2D duration group (157.74–215.15 months; upper panel) and shorter
T2D duration group (7.41–157.70 months; lower panel). In each plot, the
dashed vertical line from the x-axis is the dichotomization cut point at the
low end of the upper third for HbA1c (10.535%). Solid line in each panel
is the regression line for all participants in the T2D duration group. Dotted
lines in each panel are the regression lines for participants in the lower and
high HbA1c subgroups. For each subgroup, means and standard deviations
of HbA1c and overall cognition scores are black stars with vertical bars.
Abbreviations: HbA1c, hemoglobin A1c; T2D, type 2 diabetes.
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For the primary outcome, overall cognitive performance,
and one of three cognitive domains, attention, there was a
significant interaction between T2D duration and HbA1c.
For both interactions, relatively good cognition was associ-
ated with the combination of longer T2D duration and higher
mean HbA1c—as hypothesized. This supplements studies
where higher HbA1c alone [16–18], or longer T2DMduration alone [4,5], was found to be associated with greater
cognitive impairment. The seemingly paradoxical finding
that having both risk factors mitigated rather than exacer-
bated their separate deleterious effects on cognition is hy-
pothesized by the Protected Survivor Model. Individuals
who have maintained good cognition into very old age are
said to have successful cognitive aging (SCA). The model
proposes that a larger proportion of those with SCA have
high risk than do young-old with good cognition. Maintain-
ing good cognition into very old age despite high risk is
called resistant SCA (rSCA) [12].
The model was developed to explain unexpected findings
in studies of SCA, especially those beyond age 85 years.
Many risk factors for cardiovascular disease were consis-
tently identified in samples of young-old as also associated
with bad cognition [11]. In samples of very old individuals,
some risk factors—including HbA1c [7,14]—were rarely
associated with bad cognition and sometimes significantly
associated with good cognition: cholesterol [8,25,26], C-
reactive protein [9,15,27], blood pressure [10], apolipopro-
tein E-e4 [28,29].
In the present study, we measured survival by T2D dura-
tion rather than age. Thus, a novel feature is testing the
model in a young-old sample (mean5 70 years), in contrast
to the earlier studies of the very old. The “resistant” aspect of
rSCA can be generalized to young-old who nevertheless
have lived for a long time at high risk without the bad
outcome, comparable to individuals having SCA despite
high risk—rSCA.
An earlier study from our group, examining an Israeli
sample of nondemented patients with T2D (N5 897), found
worse cognitive performance associated with longer T2D
duration specifically in the third of the sample with the high-
est mean HbA1c measures taken over an average of
8.7 years. There was a substantial discrepancy in the samples
between the HbA1c levels of the two samples, at least partly
attributable to the eligibility requirements of the clinical trial
from which the present sample was derived. It focused spe-
cifically on those in need of better T2D self-care. The high
HbA1c group in the Israeli study ranged from 7.0% to
10.1%, which did not even overlap with the high HbA1c
group in the present sample (10.5% to 13.8%); on the con-
trary, it was comparable to the lower HbA1c group in the
present sample (range: 6.2% to 10.5%). The associations be-
tween T2D duration and overall cognition were similar
between their high group and the lower group in the present
sample (partial r 5 20.19 in both groups, indicating worse
cognition for longer duration), and statistically significant
(Israeli group, P 5 .002; present study group, P 5 .027).
Despite the appearance of inconsistency in the directions
of interactions in the two studies, the studies are not in con-
flict. This explanation for the discrepancy also applies to the
ACCORD-MIND baseline sample [30]. The negative associ-
ation between HbA1c level and cognition was found in a
sample similar to the lower group of the present study and
the high group in the Israeli study; the mean 6 standard
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levels .11% were excluded.
Our finding is an exception to the generality that high risk
is associated with impaired cognition, and it is so in the
context of an extreme subpopulation—long-term exposure
to high risk. The ACCORD study found a different excep-
tion—intensive intervention to reduce HbA1c levels was
not beneficial [31]. It illustrates the caution that association
does not imply a simple causal explanation.
There were limitations on this sample of veterans in treat-
ment who had T2D. The very small proportion of women is
representative of their rarity among veterans of this age. The
participants were enrolled in a clinical trial that required dif-
ficulties in disease management to permit improvements.
Those excluded due to very good disease management
were likely to have low levels of risk, thus their exclusion
in the present study limited the range and reduced power.
Although the risk factor measure was derived longitudinally,
the outcome cognition was measured cross-sectionally,
excluding inferences about causality.
The evaluation of T2D duration started with the date of
the first recorded CPRS measurement of HbA1c, which for
17 (11%) of the sample was below the threshold of 6.5%.
For them, T2D may have started later, but 11 of the 17 had
HbA1c levels indicating borderline diabetes, .5.7% (7 of
the 11 had HbA1c greater than 6.5% at their next assess-
ment, as did the remaining 6 of the 17 with HbA1c
,5.7%). On the other hand, 26 (17%) of the sample
(including three with first HbA1c ,6.5%) had HbA1c mea-
surements in the first year of CPRS implementation, so it is
plausible that they had beenmeasured earlier with T2D-level
values.
A pitfall built into the Protected Survivor Model is the
seeming benefit misleadingly associated with long-term
high risk. An association of high risk with good cognition de-
pends on the high proportion of protection in survivors with
high risk. Even if applicable, the Protected Survivor Model
does not identify which high risk survivors are truly protected.
Nor does the model assume that the risk factor in protected
survivors is beneficial, only that it is not as harmful as in un-
protected survivors. Moreover, the focus on cognitive perfor-
mance does not reflect other dangers of T2D. Thus, the
present findings must not be clinically interpreted for a given
individual to suggest that control of HbA1c levels becomes
less important after an extended period.
Clinical trials for protection against cognitive decline
have used a variety of potential protective factors, such as
physical activity, dietary, or cognitive engagement factors,
but without definitive results [32]. Because resistance to dis-
ease is not readily distinguished from nondiseased normality,
efforts to identify protective factors pose more challenges
than identifying risk factors. Many people may remain free
of disease owing to lack of exposure to the factors that in-
crease disease risk, rather than resistance. Affirmative pro-
tection is more likely in those who have remained healthy
despite their high exposure to risk factors. This strategy iden-tified the protective mutation in the CCR5 gene against HIV
[33]—focusing on individuals at high risk of infection who
nevertheless remained free of it. According to the Protected
Survivor Model, a relatively high proportion of the very
old individuals with rSCA have a protective factor against
cognitive decline and subsequent dementia, suggesting
focusing on them for genetic and other studies seeking pro-
tective factors. The present findings generalize this strategy
to protection against cognitive decline in the young-old by
focusing on individuals with good cognition despite high
risk over an extended T2D duration.
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1. Systematic review: Associations between risk factors
and cognition vary by age at outcome. The Protected
Survivor Model posits the existence of protective
factors in a minority of the population to explain
diminished or reversed associations in the very old.
2. Interpretation: The present results show how this
model can be successfully applied to the young-old
by indexing exposure to high risk by duration of
illness rather than by very old age.
3. Future directions: The validity of the model can be
tested by focusing on individuals with good cogni-
tion despite prolonged high risk, as suggested by
the results of this study.References
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